Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks

This article was originally published in The Tan Sheet

Executive Summary

Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.
Advertisement

Related Content

Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
Linnea
Red Yeast Rice Enforcement Actions, Product Withdrawals Underway
Pharmanex Offerings Surface In Wake Of Cholestin Cancellation
CFSAN Supplement "Disease Claims" Enforcement Authority Spelled Out
FDA Cholestin Drug Determination Remanded For Utah Court Review
FDA Cholestin Drug Determination Remanded For Utah Court Review
Pharmanex Cholestin Bar For Healthy Cholesterol Levels Launching

Topics

Advertisement
UsernamePublicRestriction

Register

PS092389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel